Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 4/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.58 |
| ▸ | F10 | P00742 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 3/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13175812 | 0.95 | HTR4 (0.69) | HTR4TDP1MAPK14F10ROCK2 | |
| SCHEMBL13175546 | 0.95 | HTR4 (0.69) | HTR4TDP1MAPK14F10PDE4A | |
| SCHEMBL13175544 | 0.94 | TDP1 (0.69) | HTR4TDP1MAPK14 | |
| SCHEMBL13846080 | 0.92 | HTR4 (0.67) | HTR4TDP1MAPK14F10ROCK2 | |
| SCHEMBL13175541 | 0.91 | HTR4 (0.66) | HTR4TDP1MAPK14F10ROCK2 | |
| SCHEMBL4052766 | 0.90 | HTR4 (0.77) | HTR4TDP1MAPK14F10HRH1 | |
| SCHEMBL12825436 | 0.90 | HTR4 (0.61) | HTR4TDP1MAPK14F10ROCK2 | |
| SCHEMBL13652963 | 0.88 | HTR4 (0.81) | HTR4TDP1MAPK14F10HRH1 | |
| SCHEMBL13846092 | 0.88 | HTR4 (0.61) | HTR4TDP1MAPK14F10ROCK2 | |
| SCHEMBL13575608 | 0.88 | HTR4 (0.61) | HTR4TDP1MAPK14F10ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| EP-1983987-B1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2008040951-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040951-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2007095188-A2 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HTR4 2753/4885TDP1 1953/4885MAPK14 370/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HTR4 2181/4885TDP1 992/4885MAPK14 447/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HTR4 2753/4885TDP1 1953/4885MAPK14 370/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HTR4 2458/4885TDP1 1914/4885MAPK14 342/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HTR4 2458/4885TDP1 1914/4885MAPK14 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.